SAN DIEGO, June 13, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that
Amit D. Munshi, the Company's
President and Chief Executive Officer, will present a corporate
update at the JMP Securities Life Sciences Conference on
Wednesday, June 19, 2019, at
1:30 PM EDT. The conference will take
place June 19-20, 2019, in
New York City.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the available presentations will be
available for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility.
Etrasimod (APD334), with potential utility in a broad range of
immune and inflammatory conditions, is being evaluated in
late-stage clinical programs in ulcerative colitis and Crohn's
disease, as well as in programs for other indications such as
atopic dermatitis. Arena is also evaluating olorinab (APD371) in a
Phase 2 program for gastrointestinal pain. Arena continues to
assess other earlier research and development stage drug
candidates, including APD418 for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "driven to," "potentially,"
"potential," "being evaluated," "evaluating for," "assess for," or
words of similar meaning, or they may be identified by the fact
that they do not relate strictly to historical or current facts.
Such forward-looking statements include, without limitation,
statements about Arena's participation in the upcoming investor
conference, audio webcasts of Arena's presentation, and Arena's
drive, focus, goals, strategy, clinical and research and
development programs, collaborations, and licenses. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include: the timing and outcome of research, development
and regulatory review is uncertain; clinical and preclinical
programs may not proceed at the time or in the manner expected or
at all; results of clinical trials and other studies are subject to
different interpretations and may not be predictive of future
results; Arena expects to need additional funds to advance all of
its programs, and you and others may not agree with the manner in
which Arena allocates its resources; and other risks related to
developing and commercializing drugs; as well as those factors
disclosed in Arena's filings with the Securities and Exchange
Commission (SEC), including but not limited to its most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-jmp-securities-life-sciences-conference-on-june-19-300866866.html
SOURCE Arena Pharmaceuticals, Inc.